1
|
Funakoshi A, Honda T. 366 Blockade of IL-17A pathway downregulates increased Glut1 expression in keratinocytes in psoriasis lesions and may reduce epidermal hyperplasia in psoriasis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Maeno H, Suzuki-Horiuchi Y, Funakoshi A, Shimizu T, Satou Y, Ishii T, Seykora J. LB1004 miR-4521 is over-expressed in human lentigos and downregulates components of the autophagic pathway in keratinocytes. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.1030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Nakazawa S, Aoshima M, Funakoshi A, Shimauchi T, Asakawa S, Hirasawa N, Tokura Y. 650 Suprabasin-deficient mice show limited but discernible defective barrier in both skin and upper digestive tract. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.659] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Suzuki T, Sakabe J, Kamiya K, Funakoshi A, Tokura Y. The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells. Clin Exp Dermatol 2018; 43:445-448. [PMID: 29392742 DOI: 10.1111/ced.13397] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Plasmacytoid dendritic cells (pDCs) are involved in the pathogenesis of psoriasis by secreting interferon-α. Vitamin D3 analogues are widely used to treat psoriasis, and the representative analogue calcipotriol (CAL) uniquely downregulates the cytokine production and chemotactic activity of pDCs. However, the molecular mechanism of action of CAL is not well understood. AIM To investigate effects of CAL on the Toll-like receptor 9-myeloid differentiation primary response gene 88 (TLR9-MyD88) signalling pathway, which induces cytokine production, in murine pDCs. METHODS pDCs were isolated from mouse spleen cells by negative selection or were generated from mouse bone-marrow cells, and were stimulated with CpG-oligodeoxynucleotide (ODN) with or without CAL for 24 h. mRNA expression of TLR9 and MyD88 was assessed by real-time PCR, and the amount of TLR9 was measured by western blotting. RESULTS CAL suppressed the CpG-ODN-induced increased expression of MyD88 and TLR9 in pDCs. CONCLUSIONS CAL may downregulate pDCs by inhibiting TLR9-MyD88 signalling.
Collapse
Affiliation(s)
- T Suzuki
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - J Sakabe
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - K Kamiya
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.,Department of Dermatology, Jichi Medical University, Tochigi, Japan
| | - A Funakoshi
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Y Tokura
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
5
|
Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol 2017; 143:1053-1059. [PMID: 28210843 PMCID: PMC5427167 DOI: 10.1007/s00432-017-2349-y] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Accepted: 01/24/2017] [Indexed: 01/05/2023]
Abstract
PURPOSE The GEST study showed non-inferiority of S-1 but not superiority of gemcitabine plus S-1 (GS) to gemcitabine alone for overall survival with the data by the cut-off date of 31st July in 2010 for chemo-naïve patients with advanced pancreatic cancer. We considered it important to determine whether S-1 maintains non-inferiority after a long-term follow-up in the GEST study and to obtain a firm positive conclusion. In addition, it may be an interesting challenge to explore the efficacious profile of GS in the long-term follow-up study. Using the data from the follow-up period, background and efficacy in patients from Taiwan and Japan, as well as the rates of tumor shrinkage in locally advanced and metastatic patients (Waterfall plot) were also analyzed. METHODS The results of the primary analysis were reconfirmed, and subset analysis of overall survival and progression-free survival was performed based on the overall survival data updated by the cut-off date of 31st July in 2011. RESULTS The median follow-up period was 29.8 months, and 795 deaths occurred (95.6%). The median overall survival was 8.8 months for gemcitabine, 9.7 months for S-1 (hazard ratio [HR], 0.96; 97.5% confidence interval [CI], 0.79-1.17), and 9.9 months for GS (HR 0.91; 97.5% CI 0.75-1.11). In patients with performance status (PS) 0, the median overall survival was 9.8 months for gemcitabine, 10.9 months for S-1, and 10.5 months for GS. In patients with PS 1, the median overall survival was 6.2 months for gemcitabine, 6.3 months for S-1, and 9.6 months for GS. CONCLUSION Our survey reconfirmed the non-inferiority of S-1 to gemcitabine and showed S-1 can be used as one of the standard treatment options for advanced pancreatic cancer. TRIAL REGISTRATION ClinicalTrials.gov: NCT00498225.
Collapse
Affiliation(s)
- Takuji Okusaka
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
| | - H Miyakawa
- Division of Biliopancreatology, Sapporo Kosei General Hospital, Sapporo, Japan
| | - H Fujii
- Division of Clinical Oncology, Jichi Medical University, Tochigi, Japan
| | - S Nakamori
- Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital, Osaka, Japan
| | - T Satoh
- Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Hamamoto
- Keio Cancer Center, Keio University Hospital, Tokyo, Japan
| | - T Ito
- Department of Medicine and Bioreguratory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - H Maguchi
- Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan
| | - S Matsumoto
- Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - H Ueno
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - T Ioka
- Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - N Boku
- Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
| | - S Egawa
- Department of Surgery, Tohoku University, Sendai, Japan
| | - T Hatori
- Department of Surgery and Digestive Diseases Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan
| | - J Furuse
- Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan
| | - K Mizumoto
- Kyushu University Hospital Cancer Center, Fukuoka, Japan
| | - S Ohkawa
- Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - T Yamaguchi
- Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan
| | - K Yamao
- Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - A Funakoshi
- Division of Pancreatology, Fukuoka Sanno Hospital, Fukuoka, Japan
| | - J S Chen
- Division of Hematology-Oncology, Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan, Republic of China
| | - A L Cheng
- Department of Oncology, National Taiwan University Hospital, and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China
| | - A Sato
- Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan
| | - Y Ohashi
- Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan
| | - M Tanaka
- Department of Surgery, Shimonoseki City Hospital, Shimonoseki, Japan
| |
Collapse
|
6
|
Ito T, Suzuki T, Funakoshi A, Fujiyama T, Tokura Y. 218 Chemokine receptor CCR5 is the novel target for the treatment of alopecia areata. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Funakoshi A, Morikawa T, Futoo E, Bessho H, Nomura T, Takano N, Shibahara T. Female patients with oral squamous cell carcinoma in Japan. J Oral Maxillofac Surg 2014. [DOI: 10.1016/j.joms.2014.06.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Chen J, Mizumoto K, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Cheng A, Okusaka T. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4007] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Makimoto A, Sato T. A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4550] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4550 Background: As shown in our previous phase I study (Oncology 2005, 69:421–427), gemcitabine and S-1 combination therapy (GS therapy) appears to be feasible and effective against advanced pancreatic cancer. The present multicenter phase II study was conducted to confirm the efficacy and toxicity of GS therapy for metastatic pancreatic cancer. Methods: Patients with histologically or cytologically proven pancreatic adenocarcinoma with at least one measurable metastatic lesion were eligible for the study. Other eligibility criteria included: no previous treatment for pancreatic cancer except surgery, age =20 and =74 years, ECOG performance status of 0 or 1, and adequate organ function. Gemcitabine was given intravenously at a dose of 1,000 mg/m2 over 30 min on days 1 and 8, and S-1 was given orally at a dose of 40 mg/m2 twice daily from day 1 to day 14, repeated every 3 weeks. The objective response rate was assessed according to RECIST. Results: A total of 55 patients from 10 institutions were enrolled between October 2004 and July 2005. The efficacy and toxicity were analyzed in 54 patients who received at least one course of GS therapy. The median number of treatment courses was 7 (range, 1–24+). Although no complete response was seen, a partial response was achieved in 24 patients, resulting in an overall response rate of 44% (95% CI, 30.9–58.6%). Twenty-six patients (48%) had stable disease. The median progression-free survival was 5.9 months (95% CI, 4.1–6.9 months) and the median overall survival was 10.1 months (95% CI, 8.5–10.8 months) with a 1-year survival rate of 33%. The major grade 3–4 toxicities were neutropenia (80%), leucopenia (59%), thrombocytopenia (22%), anorexia (17%), rash (7%), nausea (6%) and fatigue (6%). Hematological toxicity was mostly transient and there was only one episode of infection with grade 3–4 neutropenia. No treatment-related deaths occurred during the study. Conclusions: GS therapy produced a high response rate and good survival associated with an acceptable toxicity profile in patients with metastatic pancreatic cancer. A randomized phase III trial to confirm the efficacy of GS therapy is planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Ueno
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - J. Furuse
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - K. Yamao
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - A. Funakoshi
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - N. Boku
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - S. Ohkawa
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - A. Makimoto
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| | - T. Sato
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center, Aichi, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Kanagawa Cancer Center, Kanagawa, Japan; Kyoto University School of Public Health, Kyoto, Japan
| |
Collapse
|
10
|
Miyasaka K, Hosoya H, Sekime A, Ohta M, Amono H, Matsushita S, Suzuki K, Higuchi S, Funakoshi A. Association of ghrelin receptor gene polymorphism with bulimia nervosa in a Japanese population. J Neural Transm (Vienna) 2005; 113:1279-85. [PMID: 16362631 DOI: 10.1007/s00702-005-0393-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2005] [Accepted: 10/09/2005] [Indexed: 10/25/2022]
Abstract
Eating disorders (EDs) have a highly heterogeneous etiology and multiple genetic factors might contribute to their pathogenesis. Ghrelin, a novel growth hormone-releasing peptide, enhances appetite and increases food intake, and human ghrelin plasma levels are inversely correlated with body mass index. In the present study, we examined the 171T/C polymorphism of the ghrelin receptor (growth hormone secretagogue receptor, GHSR) gene in patients diagnosed with EDs, because the subjects having ghrelin gene polymorphism (Leu72Met) was not detected in a Japanese population, previously. In addition, beta3 adrenergic receptor gene polymorphism (Try64Arg) and cholecystokinin (CCK)-A receptor (R) gene polymorphism (-81A/G, -128G/T), which are both associated with obesity, were investigated. The subjects consisted of 228 Japanese patients with EDs [96 anorexia nervosa (AN), 116 bulimia nervosa (BN) and 16 not otherwise specified (NOS)]. The age- and gender-matched control group consisted of 284 unrelated Japanese subjects. The frequency of the CC type of the GHSR gene was significantly higher in BN subjects than in control subjects (chi(2) = 4.47, p = 0.035, odds ratio = 2.05, Bonferroni correction: p = 0.070), while the frequency in AN subjects was not different from that in controls. The distribution of neither beta3 adrenergic receptor gene nor CCK-AR polymorphism differed between EDs and control subjects. Therefore, the CC type of GHSR gene polymorphism (171T/C) is a risk factor for BN, but not for AN.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ishii H, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T. Retrospective analysis of systemic chemotherapy for unresectable advanced biliary tract cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Ishii
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - J. Furuse
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - T. Okusaka
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - K. Yamao
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - A. Funakoshi
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - S. Ohkawa
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - N. Boku
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - K. Tanaka
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - M. Nagase
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - H. Saisho
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| | - T. Sato
- National Cancer Ctr Hosp East, Kashiwa, Chiba, Japan; National Cancer Ctr Hosp, Tokyo, Japan; Aichi Cancer Ctr, Nagoya, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Shizuoka Cancer Ctr, Nagaizumi, Japan; Yokohama City Univ, Yokohama, Japan; Tochigi Cancer Ctr, Utsunomiya, Japan; Chiba Univ, Chiba, Japan; Kyoto Univ, Kyoto, Japan
| |
Collapse
|
12
|
Funakoshi A, Okusaka T, Ishii H, Yamao K, Ohkawa S, Saito H, Saito S, Tsuyuguchi T. A multicenter phase II study of gemcitabine (GEM) in patients with unresectable biliary tract cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4145] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Funakoshi
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - T. Okusaka
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - H. Ishii
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - K. Yamao
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - S. Ohkawa
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - H. Saito
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - S. Saito
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| | - T. Tsuyuguchi
- National Kyushu Cancer Ctr, Fukuoka, Japan; National Cancer Ctr Hosp, Chuo-ku, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa-city,Chiba, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata-city, Yamagata, Japan; Aomori Prefectural Hosp, Aomori-city, Aomori, Japan; Chiba Univ Hosp, Chuo-ku, Chiba-city, Chiba, Japan
| |
Collapse
|
13
|
Affiliation(s)
- J. Furuse
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - T. Okusaka
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - A. Funakoshi
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - N. Boku
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - K. Yamao
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - S. Ohkawa
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| | - H. Saito
- National Cancer Ctr Hosp East, Kashiwa, Japan; National Cancer Ctr Hosp, Tokyo, Japan; National Kyushu Cancer Ctr, Fukuoka, Japan; Shizuoka Cancer Ctr, Suntou-gun, Japan; Aichi Cancer Ctr, Nagoya, Japan; Kanagawa Cancer Ctr, Yokohama, Japan; Yamagata Prefectural Central Hosp, Yamagata, Japan
| |
Collapse
|
14
|
Miyasaka K, Funakoshi A, Jimi A, Sazaki N, Kitani K. Manifestations of experimental acute pancreatitis in young and old rats. Arch Gerontol Geriatr 2005; 14:167-74. [PMID: 15374401 DOI: 10.1016/0167-4943(92)90051-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/1991] [Revised: 11/13/1991] [Accepted: 11/15/1991] [Indexed: 11/21/2022]
Abstract
Two kinds of experimental pancreatitis were induced in young (4-6 month) and old (25-27 month) female Wistar rats: acute edematous pancreatitis was induced by intraperitoneal administration of a high dose of cerulein (40 micro/kg x 2) and acute hemorrhagic pancreatitis was intraductal injection of 1% deoxycholic acid. After these treatments, the plasma amylase concentration and pancreatic wet weight were determined and the pancreas was examined histologically. In the groups with cerulein induced pancreatitis one of eight old rats died, whereas all five young rats survived. There was no specific finding macroscopically in the liver, kidney, lung or heart of old rats at autopsy after cerulein injection. The plasma amylase concentration and the pancreatic wet weight were significantly increased by administration of cerulein or deoxycholic acid in both young and old rats. There was no significant difference in the plasma amylase concentrations in young and old rats after the induction of acute pancreatitis. The increase in pancreatic wet weight was less in old rats than in young ones after deoxycholic acid treatment, but similar in the two groups after cerulein injection. The extents of histological changes were also similar in young and old rats. Thus, no evidence that aging increases susceptibility to pancreatitis was obtained.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Tokyo-173, Japan
| | | | | | | | | |
Collapse
|
15
|
Funakoshi A, Okusaka T, Ishii H, Sawaki A, Ohkawa S, Ishikawa O, Saitoh S. Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Funakoshi
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - T. Okusaka
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - H. Ishii
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - A. Sawaki
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - S. Ohkawa
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - O. Ishikawa
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| | - S. Saitoh
- National Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Aichi Cancer Center, Nagoya, Japan; Kanagawa Cancer Center, Yokohama, Japan; Osaka Medical Center for Cancer & Cardiovascular, Osaka, Japan; Aomori Prefectural Central Hospital, Aomori, Japan
| |
Collapse
|
16
|
Shimazoe T, Nakamura S, Kobayashi K, Watanabe S, Miyasaka K, Kono A, Funakoshi A. Role of 5-ht1b receptors in entrainment disorder of otsuka long evans tokushima fatty (oletf) rats. Neuroscience 2004; 123:201-5. [PMID: 14667454 DOI: 10.1016/j.neuroscience.2003.08.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The role of 5-HT1A and 5-HT1B receptors in entrainment function was studied in Otsuka Long Evans Tokushima fatty (OLETF) rats and control Long Evans Tokushima Otsuka (LETO) rats. Light-induced (100 lux, 30 min) Fos expression in the suprachiasmatic nucleus was studied. Light-induced Fos expression was significantly decreased in OLETF rats compared to that in LETO rats. The decrease of light-induced Fos expression in OLETF rats was significantly reversed by pretreatment with the 5-HT1B receptor antagonist, isamoltan (3 mg/kg, i.p.). Simultaneous administration of CGS12066B (5 mg/kg, i.p.), a 5-HT1B agonist, blocked the reversal effect of isamoltan on Fos expression. Fos expression was not changed in LETO rats by pretreatment with isamoltan (3 mg/kg, i.p.). The Fos expression in LETO and OLETF rats was significantly decreased by pretreatment with the 5-HT1A antagonist, WAY-100,635. Phase shifts in locomotor activity paralleled the Fos expression. Light-induced phase shifts of locomotor activity in OLETF rats were significantly smaller than those in LETO rats. The phase shifts were significantly increased by isamoltan (3 mg/kg, i.p.) in OLETF rats. These results suggest that 5-HT1B receptors are involved in the reduced entrainment function of OLETF rats.
Collapse
Affiliation(s)
- T Shimazoe
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 812-8582, Fukuoka, Japan.
| | | | | | | | | | | | | |
Collapse
|
17
|
Iguchi H, Yokota M, Fukutomi M, Uchimura K, Yonemasu H, Hachitanda Y, Nakao Y, Tanaka Y, Sumii T, Funakoshi A. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2002; 21:309-13. [PMID: 12385570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
The incidence of bone metastasis was around 13% in 404 patients with hepatocellular carcinoma (HCC) who underwent treatment at the National Kyushu Cancer Center between 1988-97, which is a high value among various cancers. This is, in part, due to the prolonged survival time of HCC patients in recent years. Serum vascular endothelial growth factor (VEGF) levels were significantly elevated in HCC patients with bone metastases as compared to those in patients with liver cirrhosis/chronic hepatitis and HCC patients without bone metastasis. VEGF was positively stained in both the primary lesion and bone metastasis of HCC by immunohistochemistry. In the process of bone metastasis, an increase in bone resorption is a crucial step prior to invasion of the bone. VEGF, the most important angiogenic factor, has been shown to stimulate bone resorption through its effects on osteoclasts. Thus, HCC cells reach the bone marrow space, and then secrete VEGF which facilitates osteolytic bone metastasis. VEGF may also facilitate tumor growth in the bone by acting as an angiogenic factor once invasion of the bone is complete. This might be another reason for the high incidence of bone metastasis in HCC.
Collapse
Affiliation(s)
- H Iguchi
- Division of Biochemistry, National Kyushu Cancer Center Research Institute, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Miyasaka K, Masuda M, Kanai S, Ohta M, Suzuki S, Tateishi K, Funakoshi A. Inhibitory effect of somatostatin on cholecystokinin release is independent of luminal cholecystokinin-releasing factor content in conscious rats. Pancreas 2001; 23:414-20. [PMID: 11668212 DOI: 10.1097/00006676-200111000-00013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
INTRODUCTION Exclusion of bile-pancreatic juice from the intestine increases pancreatic secretion via cholecystokinin (CCK) release in conscious rats. Luminal CCK-releasing factor (LCRF), purified from rat intestinal secretions, is an intraluminal regulator of CCK secretion during bile-pancreatic juice diversion. AIMS Because somatostatin is a potent inhibitor of CCK release and pancreatic secretion, the inhibitory effect of somatostatin on LCRF was examined. METHODOLOGY Rats were prepared with bile and pancreatic cannulae and two duodenal cannulae and with an external jugular vein cannula. The experiments were conducted without anesthesia. After 1.5-hour basal collection of pancreatic juice with bile-pancreatic juice return, bile-pancreatic juice was diverted for 2 hours, during which time somatostatin (2, 10 nmol/kg/h) was infused intravenously. The rats were killed before and 1 and 2 hours after bile-pancreatic juice diversion. To examine the effect of luminal somatostatin, 50 or 200 nmol/kg/h of somatostatin was infused into the duodenum. The plasma CCK and luminal content of LCRF were measured by specific radioimmunoassays. RESULTS Bile-pancreatic juice diversion significantly increased pancreatic secretion, plasma CCK, and LCRF levels. Intravenous infusion of somatostatin inhibited CCK release and pancreatic secretion, but not LCRF content. Luminal administration of somatostatin did not show any effect. CONCLUSION Inhibitory effect of circulating somatostatin on CCK release and pancreatic secretion is independent of LCRF content.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashiku, Tokyo-173-0015, Japan.
| | | | | | | | | | | | | |
Collapse
|
19
|
Suzuki S, Takiguchi S, Sato N, Kanai S, Kawanami T, Yoshida Y, Miyasaka K, Takata Y, Funakoshi A, Noda T. Importance of CCK-A receptor for gallbladder contraction and pancreatic secretion: a study in CCK-A receptor knockout mice. Jpn J Physiol 2001; 51:585-90. [PMID: 11734079 DOI: 10.2170/jjphysiol.51.585] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Bile and pancreatic secretions were determined in a CCK-A receptor deficient mouse mutant generated by gene targeting in embryonic stem cells. The targeting vector contained lacZ and neo insertions in exon 2. Under the urethane anesthesia, the common bile duct was cannulated, and the mixture of bile-pancreatic juice was collected every 30 min. After the 1 h basal secretion, CCK-8 (0.5 and 1.0 nmol/kg), acetylcholine (500 nmol/kg), and neuromedin C (1.0 micromol/kg) were injected subcutaneously, and the secretions were collected following 1 h. Amylase and bile acid outputs were determined as parameters of pancreatic secretion and gallbladder contraction, respectively. In some CCK-A receptor (+/-) animals, LacZ staining was performed. CCK-8 significantly increased amylase and bile acid outputs in CCK-A receptor (+/+) and (+/-) mice, whereas no response was observed in (-/-) mice. Neuromedin C and acetylcholine increased amylase secretion in CCK-A receptor (-/-) mice similar to (+/-) and (+/+) mice. The same doses of neuromedin C and acetylcholine could not increase bile acid secretion. The gallbladder smooth muscles, pancreatic acinar cells, duct cells, and islets were stained by LacZ. CCK and CCK-A receptor are important for pancreatic secretion and gallbladder contraction. Neuromedin C and acetylcholine may compensate pancreatic function, but not gallbladder contraction.
Collapse
Affiliation(s)
- S Suzuki
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, 173-0015 Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
OBJECTIVES Recently, we often encounter hepatocellular carcinoma patients with bone metastases. We therefore examined the changes in the incidence of bone metastases in hepatocellular carcinoma from 1978 to 1997 and tried to identify the characteristic clinical features. We also discuss the reasons for the increased incidence of bone metastasis in hepatocellular carcinoma. METHODS A total of 673 patients with hepatocellular carcinoma during the period 1978-1997 were studied. Bone metastasis was screened by bone scintigraphy, and bone lesions were confirmed by plain radiography, computed tomography and/or magnetic resonance imaging. The serum levels of the C-terminal telopeptide of type 1 collagen, which represent osteoclastic bone resorption, were also measured. RESULTS The incidence of bone metastasis during the decade 1988-1997 was significantly higher than that during the period 1978-1987. The median survival time of patients with hepatocellular carcinoma during 1988-1997 was also significantly longer than that during 1978-1987. Portal thrombus was found in about half of the patients with bone metastases. The most common site of bone metastases was the vertebra followed by the pelvis, rib and skull in that order. All bone lesions depicted by plain radiograph, computed tomography and/or magnetic resonance imaging were of the osteolytic type, and the serum levels of C-terminal telopeptide of type 1 collagen were significantly elevated in the patients with bone metastases. CONCLUSIONS The increased incidence of bone metastasis in hepatocellular carcinoma in the decade 1988-1997 is first attributed to the prolonged survival rate of hepatocellular carcinoma patients due to recent progress in both the diagnosis and treatment of the disease. Dissemination of hepatocellular carcinoma cells to the vertebra through the portal vein-vertebral vein plexuses due to the presence of portal thrombus and/or portal hypertension may be related to a higher incidence of bone metastasis in hepatocellular carcinoma. Both an early diagnosis and timely treatment of bone metastases are thus called for in the follow-up of hepatocellular carcinoma patients.
Collapse
Affiliation(s)
- M Fukutomi
- Division of Gastroenterology, National Kyushu Cancer Centre, Notame 3-1-1, Minami-ku, Fukuoka 811-1395, Japan
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Kurosawa M, Iijima S, Funakoshi A, Kawanami T, Miyasaka K, Bucinskaite V, Lundeberg T. Cholecystokinin-8 (CCK-8) has no effect on heart rate in rats lacking CCK-A receptors. Peptides 2001; 22:1279-84. [PMID: 11457521 DOI: 10.1016/s0196-9781(01)00452-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Heart rate responses to i.v. administration of cholecystokinin-8 (CCK-8) were investigated in Otsuka Long-Evans Tokushima Fatty (OLETF) rats lacking CCK-A receptors and control Long-Evans Tokushima Otsuka (LETO) rats. The heart rate decreased after i.v. administration of 3 nmol.kg(-)(1) of CCK-8 in LETO rats, but not in OLETF rats. Bradycardia in the LETO rats disappeared after treatment with MK-329, but not after treatment with L-365,260. The expression of CCK-A receptor precursor mRNA was found exclusively in the atrium in LETO rats. These results suggest that CCK-8 decreases heart rate via CCK-A receptors located in the atrium of the rats.
Collapse
MESH Headings
- Animals
- Benzodiazepinones/pharmacology
- Blotting, Southern
- Bradycardia
- DNA, Complementary/metabolism
- Devazepide/pharmacology
- Dose-Response Relationship, Drug
- Heart Atria/metabolism
- Heart Rate/drug effects
- Hormone Antagonists/pharmacology
- Male
- Phenylurea Compounds/pharmacology
- Polymerase Chain Reaction
- RNA, Messenger/metabolism
- Rats
- Rats, Inbred OLETF
- Rats, Long-Evans
- Receptor, Cholecystokinin A
- Receptors, Cholecystokinin/biosynthesis
- Receptors, Cholecystokinin/genetics
- Receptors, Cholecystokinin/physiology
- Sincalide/metabolism
- Sincalide/pharmacology
- Time Factors
Collapse
Affiliation(s)
- M Kurosawa
- Basic Medical Research Center, International University Health and Welfare, Otawara, Tochigi 324-8501, Japan.
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
BACKGROUND Pancreatic carcinoma is often associated with diabetes mellitus. The interrelationship between them is very interesting and important for clinical examination and treatment. METHODS We examined diabetes mellitus in our patients with pancreatic carcinoma, especially those with invasive ductal pancreatic carcinoma, who were admitted to the National Kyushu Cancer Center between 1972 and 1998, in relation to secondary (pancreatic) diabetes, obstructive pancreatitis, angiopathies, treatment, and prognosis. RESULTS Diabetes mellitus was found at a high frequency (53.1%) in patients with invasive ductal pancreatic carcinoma and was mostly thought to be secondary diabetes (45.9%), caused, in part, by obstructive pancreatitis following pancreatic tumor recognized on the first admission. Control of blood glucose with insulin was sometimes difficult, but was indispensable for the treatment of pancreatic carcinoma. Diabetic angiopathies are usually not seen in patients with pancreatic diabetes caused by pancreatic carcinoma, because the survival period of patients with pancreatic carcinoma has been limited. Furthermore, in spite of the absence of angiopathies, the survival period was significantly lower in pancreatic carcinoma patients with diabetes than in those without diabetes. CONCLUSION Diabetes in patients with invasive ductal pancreatic carcinoma is usually secondary diabetes, occurring in part as a consequence of obstructive pancreatitis shown at the beginning of the clinical course. The duration of diabetes is too short for marked diabetic angiopathies to develop, and the survival period in patients with invasive ductal pancreatic carcinoma with diabees is also short compared with that of those patients without diabetes.
Collapse
Affiliation(s)
- H Wakasugi
- Department of Gastroenterology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
| | | | | |
Collapse
|
23
|
Tajima T, Funakoshi A, Ikeda Y, Hachitanda Y, Yamaguchi M, Yokota M, Yabuuchi H, Satoh T, Koga M. Nonfunctioning adrenal rest tumor of the liver: radiologic appearance. J Comput Assist Tomogr 2001; 25:98-101. [PMID: 11176302 DOI: 10.1097/00004728-200101000-00018] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We describe the radiologic features of an adrenal rest tumor of the liver. The adrenal rest tumor appeared on ultrasound as a round, well defined, heterogeneous, solid mass in the posterior aspect of the liver, on angiography as a homogeneous hypervascular mass, and on dynamic CT as a mass containing components of both fat density and soft tissue density and showing early fill-in and early fill-out. Adrenal rest tumors should be included in the lists of hypervascular or fat-containing masses in the liver.
Collapse
Affiliation(s)
- T Tajima
- Department of Radiology, National Kyushu Cancer Center, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Yukawa E, Hokazono T, Funakoshi A, Yukawa M, Ohdo S, Higuchi S, Ichimaru R, Makit T, Matsunaga K, Anai M, Goto Y. Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Psychopharmacol 2000; 20:685-90. [PMID: 11106142 DOI: 10.1097/00004714-200012000-00016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The steady-state trough concentrations of haloperidol were studied to clarify the role of the characteristics of Japanese patients in estimating haloperidol dosing regimens by using routine therapeutic drug-monitoring data. Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effect of a variety of developmental and demographic factors on haloperidol clearance values using 270 serum level measurements obtained from 191 patients during their clinical course. The final model describing haloperidol's relative clearance was CL = 0.74 x TBW(0.594) x DOSE(0.326) x 1.32CO1 x 0.867AGE, where CL is clearance (measured in liters per hour), TBW is the total body weight (in kilograms), DOSE is the daily dose of haloperidol (in grams per kilogram per day), CO1 = 1 for concomitant administration of antiepileptic drugs (phenobarbital, phenytoin, or carbamazepine) and CO1 = 0 otherwise, and AGE = 1 for patients aged 55 years or older and AGE = 0 otherwise. Concomitant administration of haloperidol and antiepileptic drugs resulted in a 32% increase in haloperidol clearance. Patients aged 55 years or older showed a 13.3% reduction in clearance values compared with the younger population.
Collapse
Affiliation(s)
- E Yukawa
- Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- H Kawai
- Department of Gastroenterology, National Kyushu Cancer Center Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
26
|
Kurosawa M, Bucinskaite V, Miyasaka K, Funakoshi A, Lundeberg T. Effects of systemic injection of interleukin-1beta on gastric vagal afferent activity in rats lacking type A cholecystokinin receptors. Neurosci Lett 2000; 293:9-12. [PMID: 11065125 DOI: 10.1016/s0304-3940(00)01479-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We have shown that systemic administration of interleukin-1beta (IL-1beta) excites gastric vagal afferent activity in part via stimulation of type A cholecystokinin (CCK-A) receptors in rats. The present study was undertaken to determine whether the response of the gastric vagal afferent nerve to systemic IL-1beta is altered in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which lack CCK-A receptors. The response was compared with that of the control strain, Long-Evans Tokushima Otsuka (LETO) rats. All animals were anesthetized with pentobarbital and artificially ventilated. Intravenous administration of 4 microg/kg of IL-1beta increased gastric vagal afferent activity in both LETO and OLETF rats, whereas a smaller dose of 2 microg/kg of IL-1beta increased activity only in the OLETF rats. The present results demonstrate that the response of the gastric vagal afferent activity in CCK-A receptor deficient OLETF rats was more sensitive to intravenous administration of IL-1beta than was in control LETO rats.
Collapse
Affiliation(s)
- M Kurosawa
- Basic Medical Research Center, International University Health and Welfare, Otawara, Tochigi, Japan.
| | | | | | | | | |
Collapse
|
27
|
Miyasaka K, Kanai S, Ohta M, Jimi A, Kono A, Funakoshi A. Overexpression of cholecystokinin-B/gastrin receptor gene in the stomach of naturally occurring cholecystokinin-A receptor gene knockout rats. Digestion 2000; 59:26-32. [PMID: 9468095 DOI: 10.1159/000007463] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We examined the cholecystokinin (CCK)-B/gastrin receptor, H+/K+-ATPase and somatostatin gene expression, the histology and immunohistochemistry of gastrin and somatostatin of the stomach, plasma gastrin levels, and gastric acid secretion in naturally occurring CCK-A receptor gene knockout (Otsuka Long-Evans Tokushima fatty, OLETF) rats. The CCK-B/ gastrin receptor, H+/K+-ATPase and somatostatin mRNAs were determined by Northern transfer analysis. The gastric acid secretion and the plasma gastrin level were measured in vivo. The levels of CCK-B/gastrin receptor mRNA in the forestomach and the glandular stomach in OLETF rats were 2-fold higher than those of control rats, although those of H+/ K+-ATPase and somatostatin mRNAs were not different. Histological examination revealed thickening of the fundic mucosa, and hyperplasia and hypertrophy of parietal cells, although immunohistochemistry of gastrin and somatostatin revealed no significant difference from the control rats. Gastric acid secretion stimulated by gastrin or histamine was enhanced, whereas the fasting plasma gastrin level was not significantly different from that in control rats. The overexpression of CCK-B/gastrin receptor mRNA and the hyperfunction of parietal cells were observed in rats without CCK-A receptor gene expression.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan.
| | | | | | | | | | | |
Collapse
|
28
|
Ichikawa M, Kanai S, Ichimaru Y, Funakoshi A, Miyasaka K. The diurnal rhythm of energy expenditure differs between obese and glucose-intolerant rats and streptozotocin-induced diabetic rats. J Nutr 2000; 130:2562-7. [PMID: 11015490 DOI: 10.1093/jn/130.10.2562] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Otsuka Long Evans Tokushima Fatty (OLETF) rats were developed as a model of noninsulin-dependent diabetes mellitus (NIDDM) with mild obesity. Changes in carcass composition and in the daily profile of energy expenditure were examined before and after manifestation of diabetes (8 and 24 wk, respectively), and compared with the normal control Long Evans Tokushima (LETO) rats and streptozotocin (STZ)-induced diabetic LETO rats. OLETF rats had greater body weights than LETO rats and significantly greater absolute and relative fat weights. A diurnal rhythm of energy expenditure associated with two peaks was observed in LETO rats, but the two peaks were not apparent in OLETF rats at 24 wk of age. A diurnal rhythm associated with one peak was observed in STZ-induced diabetic LETO rats. Energy derived from fat constituted this peak; the pattern of the daily energy expenditure was significantly different from that of either nontreated LETO or OLETF rats at 24 wk of age. NIDDM in OLETF rats at 24 wk of age has only a small role in modification of the diurnal rhythm of energy expenditure, whereas STZ-induced diabetes significantly affected the rhythm.
Collapse
Affiliation(s)
- M Ichikawa
- Department of Nutrition, Tokyo Metropolitan Institute of Gerontology, Tokyo-173-0015, Japan
| | | | | | | | | |
Collapse
|
29
|
Ohta M, Kanai S, Sato Y, Masuda M, Takahashi T, Jimi A, Funakoshi A, Miyasaka K. Mechanism of delayed gastric emptying in naturally occurring CCK-A receptor gene knockout (OLETF) rats. Jpn J Physiol 2000; 50:443-8. [PMID: 11082543 DOI: 10.2170/jjphysiol.50.443] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We recently found a specific strain of rats (OLETF rats) in which CCK-A receptor gene expression is lacking because of a genetic abnormality. As delayed gastric emptying has been reported in this strain, we examined its mechanism. A liquid gastric load containing phenol red was administered using an orogastric tube into the stomach in OLETF and control (LETO) rats. The stomach was removed 0, 15, 30 and 45 min after meal ingestion and the content of phenol red was measured to estimate the rate of gastric emptying. Pretreatment of reserpine enhanced gastric emptying in both strains. A tenfold dose of reserpine was required in OLETF rats to induce a similar effect to LETO rats. The plasma noradrenalin level was significantly higher in OLETF than LETO rats. When the smooth muscle of the stomach was isolated and contraction in vitro was examined, the smooth muscle functions were not deteriorated in OLETF rats. The thickness of muscle determined by hematoxylin-eosin staining was not different between strains. It is suggested that the delayed gastric emptying in OLETF rats may be due to increased sympathetic nerve function.
Collapse
Affiliation(s)
- M Ohta
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Tokyo, 173-0015 Japan
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Shimazoe T, Ishida J, Maetani M, Yakabe T, Yamaguchi M, Miyasaka K, Kono A, Watanabe S, Funakoshi A. Entrainment function in the suprachiasmatic nucleus of streptozotocin-induced diabetic rats. Jpn J Pharmacol 2000; 83:355-8. [PMID: 11001184 DOI: 10.1254/jjp.83.355] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
The term for re-entrainment to a new light-dark cycle in streptozotocin (STZ)-induced diabetic rats was significantly longer than that in control rats. In STZ-induced diabetic rats, the same level of phase delay in the suprachiasmatic nucleus neuronal firing rhythm was observed in control rats after glutamate application. Therefore, 5-HT function in the hypothalamus is thought to be decreased in STZ-induced diabetic rats. These results suggest that postsynaptic neuronal function is still maintained in the suprachiasmatic nucleus of STZ-induced diabetic rats. Therefore, 5-HT mechanisms may play an important role in the maintenance of this function.
Collapse
Affiliation(s)
- T Shimazoe
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Whether acute pancreatitis induced by cerulein was aggravated in human interleukin 6 (IL-6) transgenic mice and whether a specific anti-IL-6 receptor antibody improved pancreatitis were investigated. To induce acute pancreatitis, cerulein (50 microg/kg, seven injections) with or without 1 mg/kg lipopolysaccharides (LPS) was injected intraperitoneally every hour. In some mice, a monoclonal anti-IL-6 receptor antibody was administered before the first cerulein injection. The animals were killed 1 hour after the last injection. The pancreatic wet weight induced by cerulein alone was significantly higher in IL-6 transgenic mice compared with wild-type mice, but pretreatment with a specific anti-IL-6 receptor antibody did not reduce interstitial edema. When cerulein was administered with LPS, the pancreatic wet weight increased much more than when pancreatitis was induced by cerulein alone in both genotypes, and pretreatment with the anti-IL-6 receptor antibody decreased the pancreatic edema only in human-IL-6 transgenic mice. These results suggest that anticytokine antibodies may be effective in improving acute pancreatitis.
Collapse
Affiliation(s)
- S Suzuki
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan
| | | | | | | |
Collapse
|
32
|
Funakoshi A, Fukamizu Y, Miyasaka K. Mechanism of cholecystokinin-A- receptor antagonist on human pancreatic exocrine secretion. Localization of CCK-A receptor in the human duodenum. Digestion 2000; 60 Suppl 1:75-80. [PMID: 10026437 DOI: 10.1159/000051459] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Expressions of the cholecystokinin (CCK)-A and -B receptor genes in human duodenum, pancreas and gallbladder were examined by Northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR) followed by Southern blot hybridization. The autoradiographic study of CCK-A and -B receptors in the human duodenum and pancreas was examined in vitro. To determine the subtypes to CCK receptors in the pancreas or duodenum, we studied the abilities of CCK-A and -B receptor agonists (CCK-8 and gastrin) and antagonists (loxiglumide, L-364,718 and L-365,260) to inhibit binding of 125I-CCK-8. CCK-A receptor mRNA was not expressed in the human pancreas, but was expressed in the gallbladder and duodenum, although it was expressed in the pancreas by RT-PCR. CCK-B receptor mRNA was expressed in the pancreas, but not in gallbladder and duodenum. Using autoradiography, high concentrations of CCK-A receptors were detected in the duodenal mucosa, although in the pancreas only CCK-B receptors were detected by this method. These results suggest that localization of CCK-A receptor in human duodenum provides a biochemical and morphological basis for some physiological functions of CCK.
Collapse
Affiliation(s)
- A Funakoshi
- Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan.
| | | | | |
Collapse
|
33
|
Kawanami T, Funakoshi A, Suzuki S, Kanai S, Sato Y, Miyasaka K. Oral administration of a synthetic trypsin inhibitor increases pancreatic duct function in CCK-A receptor-deficient rats. Pancreas 2000; 20:394-400. [PMID: 10824695 DOI: 10.1097/00006676-200005000-00010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
The effects of oral administration of a synthetic trypsin inhibitor on bicarbonate secretion were examined in cholecystokinin A (CCK-A) receptor-deficient (OLETF) rats and compared with Wistar rats. Rats were fed chow containing 0.1% trypsin inhibitor for 7 days. Rats were prepared with cannulae draining bile and pancreatic juice separately and with duodenal and extrajugular vein cannulae after 3-day trypsin inhibitor ingestion. Then the animals were maintained in Bollman cages, and the experiments were conducted 4 days after surgery. After 1.5 h of basal secretion with bile-pancreatic juice return, bile-pancreatic juice was diverted for 2 h. The responses of bicarbonate secretion to bile-pancreatic juice diversion were significantly enhanced in rats treated with trypsin inhibitor compared with those given a control diet, whereas responses of fluid and protein secretion were not affected in OLETF rats. The response of protein secretion, but not those of fluid or bicarbonate secretion, was enhanced in Wistar rats by treatment with trypsin inhibitor. Carbonic anhydrase II gene expression was increased by 7-day treatment with trypsin inhibitor only in OLETF rats, and not in Wistar rats.
Collapse
Affiliation(s)
- T Kawanami
- Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|
34
|
Kanai S, Masuda M, Suzuki S, Ohta M, Yoshida Y, Funakoshi A, Miyasaka K. Inhibitory effect of central calcitonin-gene related peptide (CGRP) on pancreatic secretion in conscious rats. Jpn J Physiol 2000; 50:243-8. [PMID: 10880881 DOI: 10.2170/jjphysiol.50.243] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The inhibitory effect of central administration of calcitonin-gene related peptide (CGRP) on pancreatic secretion stimulated by bile-pancreatic juice diversion was determined in conscious rats. Rats were prepared with separate cannulae for draining bile and pancreatic juice and with a duodenal cannula and an extrajugular vein cannula. In addition, another cannula was stereotactically implanted into the left lateral cerebral ventricle. Rats were placed in restraint cages and experiments were conducted 4 d after the operation without anesthesia. An injection of CGRP (1 nmol/10 microl) into the left lateral cerebral ventricle (i.c.v.) inhibited pancreatic secretion as well as cholecystokinin (CCK) release induced by bile-pancreatic juice diversion. Intravenous infusion of alpha- and beta-adrenergic receptor antagonist, phentolamine and propranolol did not reverse the inhibition of pancreatic secretion. Intravenous infusion of CGRP did not affect pancreatic secretion or plasma CCK concentrations. The inhibitory action of central CGRP (i. c.v.) on pancreatic secretion and CCK release stimulated by bile-pancreatic juice diversion is partially mediated by an alpha-adrenergic mechanism, although its precise mechanism has not been elucidated.
Collapse
Affiliation(s)
- S Kanai
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Tokyo, 173-0015 Japan
| | | | | | | | | | | | | |
Collapse
|
35
|
Shimokata H, Yamada Y, Nakagawa M, Okubo R, Saido T, Funakoshi A, Miyasaka K, Ohta S, Tsujimoto G, Tanaka M, Ando F, Niino N. Distribution of geriatric disease-related genotypes in the National Institute for Longevity Sciences, Longitudinal Study of Aging (NILS-LSA). J Epidemiol 2000; 10:S46-55. [PMID: 10835828 DOI: 10.2188/jea.10.1sup_46] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Phenotypes of various genes related to geriatric diseases and the aging process were assessed in the National Institute for Longevity Sciences, Longitudinal Study of Aging (NILS-LSA). The subjects were 1,297 participants in the NILS-LSA. They were community-living males and females aged 40 to 79 years who were randomly selected from the area of the NILS. Genotypic and allelic frequencies of genes in the subjects were analyzed. Age and gender differences in the distribution of genotypes were also tested. The genotypic frequencies were as follows: (1) Angiotensin I-converting enzyme (ACE) genotype was I/I 46.2%, I/D 38.3% and D/D 15.5%. (2) alpha 1-adrenoreceptor genotype was C/C 84.4%, C/T 12.7%, and T/T 3.0%. (3) Apolipoprotein E genotype was epsilon 2/epsilon 2 0%, epsilon 2/epsilon 3 7.9%, epsilon 3/epsilon 3 70.0%, epsilon 3/epsilon 4 20.8%, epsilon 2/epsilon 4 0%, and epsilon 4/epsilon 4 1.4%. (4) Cholecystokinin type-A receptor (CCKAR) nucleotide-81 (nt-81) genotype was A/A 59.1%, A/G 35.1%, and G/G 5.9%. The CCKAR nucleotide-128 genotype (nt-128) was G/G 74.3%, G/T 23.6%, and T/T 2.2%. The combination of nucleotide (nt-81, nt-128) was (A/A, G/G) 59.1%, (A/G, G/G) 14.1%, (G/G, G/G) 1.1%, (A/G, G/T) 21.0%, (G/G, G/T) 2.6%, and (G/G, T/T) 2.1%. There were no subjects with (A/A, G/T), (A/A, T/T) or (A/G, T/T) genotypic combinations. (5) beta 3-adrenoreceptor genotype was T/T 66.8%, T/A 28.5%, and A/A 4.7%. (6) Dihydrolipoamide succinyltransferase (DLST) nucleotide 19117 genotype was A/A 25.1%, A/G 49.7%, and G/G 25.1%. The DLST nucleotide 19183 genotype was C/C 55.8%, C/T 38.2%, and T/T 5.9%. The combination of nucleotide (nt19117, nt19183) was (A/A, C/C) 6.7%, (A/G, C/C) 24.1%, (G/G, C/C) 25.1%, (A/G, C/T) 25.6%, (A/A, T/T) 5.9%, and (A/A, C/T) 12.6%. There were no subjects with (A/G, T/T), (G/G, T/T) or (G/G, T/C) genotypic combinations. (7) Transforming growth factor-beta 1 genotype T/T 35.2%, T/C 44.6%, and C/C 20.2%. (8) The platelet-activating factor acetylhydrolase genotype was M/M 71.7%, M/m 27.2%, and m/m 1.2%. The mitochondria DNA 5178 genotype A was 42.1% and C was 57.9%. There were no significant gender or age differences in tested genotypic and allelic distribution except for the DLST and apolipoprotein E. Differences in the genotypic frequencies of distribution using the Hardy-Weinberg equilibrium were significant in the ACE and alpha 1-adrenoreceptor genotypes.
Collapse
Affiliation(s)
- H Shimokata
- Department of Epidemiology, National Institute for Longevity Sciences, Aichi, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Funakoshi A, Miyasaka K. [Cholecystokinin (CCK) type-A receptor gene abnormality and life style related diseases]. Nihon Shokakibyo Gakkai Zasshi 2000; 97:311-8. [PMID: 10741155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- A Funakoshi
- Department of Gastroenterology, National Kyushu Cancer Center
| | | |
Collapse
|
37
|
Hayashi H, Sato Y, Kanai S, Masuda M, Ohta M, Funakoshi A, Nagao K, Imaizumi K, Miyasaka K. Lymphatic lipid transport is not impaired in ageing rat intestine. Mech Ageing Dev 2000; 113:219-25. [PMID: 10714940 DOI: 10.1016/s0047-6374(99)00110-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Lymphatic lipid transport in the intestine of adult and ageing rats was compared. Adult (8-10 months old) and old (24-26 months old) male Wistar rats were cannulated into the mesenteric lymph under ethrane anesthesia. On the following day, lipid emulsion containing 35.4 mg/h of olive oil was infused intraduodenally for 7 h and lymph collected hourly was assayed for triglyceride and apolipoprotein A-IV (apo A-IV). The results showed there was no difference in lymphatic lipid and apo A-IV transport between adult and old rats. Since apo A-IV synthesis in the enterocytes is linked to the intracellular assembly of lipoprotein, it is likely that in addition to lymphatic transport, production of chylomicrons is not impaired in ageing rats.
Collapse
Affiliation(s)
- H Hayashi
- Department of Internal Medicine, Yokohama Red Cross Hospital, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Funakoshi A, Miyasaka K, Matsumoto H, Yamamori S, Takiguchi S, Kataoka K, Takata Y, Matsusue K, Kono A, Shimokata H. Gene structure of human cholecystokinin (CCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett 2000; 466:264-6. [PMID: 10682840 DOI: 10.1016/s0014-5793(00)01080-2] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The transcriptional start site of the human cholecystokinin (CCK)-A receptor gene was determined by the Capsite Hunting method. Two sequence changes were detected, a G to T change in nucleotide -128, and an A to G change in nucleotide -81. The homozygote (T/T, G/G) was detected in 25 of 1296 individuals (1.9%) in the cohort study. This polymorphism showed a significantly higher percent body fat and higher levels of serum insulin and leptin, compared with wild type and heterozygotes. Our study provided the possibility that polymorphism in the promoter region of the CCK-A receptor gene may be one of genetic factors affecting fat deposition.
Collapse
Affiliation(s)
- A Funakoshi
- Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
The basal exocrine secretion of the pancreas is maintained at a constant level in conscious rats. We examined the changes in basal secretion with respect to the effect of various time periods of pancreatic duct occlusion (PDL). Male Wistar rats were prepared with cannulae that separately drained bile and pancreatic juice as well as with a duodenal cannula. Rats were placed in restraint cages, and experiments were conducted without anesthesia 4 days after the operation. Cholecystokinin (CCK) release was artificially prevented by the continuous infusion of bile with trypsin into the duodenal lumen throughout the experimental period to avoid the modification of pancreatic response by CCK. After 2-h basal collection, a pancreatic secretion was interrupted for 0.5-4 h, and then the collection of pancreatic juice was initiated again for an additional 2-4.5 h. The pancreatic secretion after the reopening of the 0.5-to 3-h PDL was comparable to basal secretion levels. However, protein secretion was significantly inhibited after the removal of 4-h PDL. Both vagotomy and capsaicin treatment abolished this inhibition, and the protein secretion after 1-h PDL in vagotomized rats increased 1.5-fold high compared with the basal value. These observations indicate that protein secretion was ceased during PDL via vagal nerve, and this may be a self-protective mechanism.
Collapse
Affiliation(s)
- S Suzuki
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan
| | | | | | | | | |
Collapse
|
40
|
Abstract
The incidence of invasive ductal carcinoma of the pancreas was 3.1% (6 cases) in 196 patients with definite chronic pancreatitis. Five patients (3 men and 2 women) had calcific pancreatitis and 1 patient (man) had non-calcific pancreatitis. Large pancreatic stones were recognized in 2 women. Most of the patients complained of continuous intractable abdominal pain and/or back pain together with weight loss and appetite loss. Serum CA19-9 levels and exacerbation of glucose intolerance were retrospectively noted to have been elevated in 1 patient. However, it was difficult to obtain a definitive diagnosis by imaging examinations earlier, due to the presence of chronic pancreatitis. Median survival of the 6 patients was 6.5 months from admission.
Collapse
Affiliation(s)
- H Wakasugi
- Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
A 57-year-old man with renal cell carcinoma and erythrocytosis showed a high serum level of erythropoietin (EPO). High EPO signal was observed on Northern blot analysis and RT-PCR in the total RNA extracted from the renal tumor. Immunohistochemical staining also demonstrated tumor tissue with high immunostaining of EPO. Nucleotide sequences of EPO cDNA in the tumor were normal. To date, only one report has discussed the nucleotide sequences of a tumor's EPO gene; it showed mutant EPO cDNA in hepatocellular carcinoma tissue. This is the first demonstration of normal EPO cDNA in renal cell carcinoma.
Collapse
Affiliation(s)
- Y Noguchi
- Department of Hematology, National Kyushu Cancer Center Hospital, Fukuoka
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Funakoshi A. [Human pancreatic polypeptide (hPP)]. Nihon Rinsho 1999; 57 Suppl:349-52. [PMID: 10778136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- A Funakoshi
- Department of Gastroenterology, National Kyushu Cancer Center
| |
Collapse
|
43
|
Kawanami T, Suzuki S, Yoshida Y, Kanai S, Takata Y, Shimazoe T, Watanabe S, Funakoshi A, Miyasaka K. Different effects of trypsin inhibitors on intestinal gene expression of secretin and on pancreatic bicarbonate secretion in CCK-A-receptor-deficient rats. Jpn J Pharmacol 1999; 81:339-45. [PMID: 10669038 DOI: 10.1254/jjp.81.339] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The effects of oral administration of two synthetic trypsin inhibitors (camostate and ONO-3403) and soybean trypsin inhibitor (SBTI) on cholecystokinin (CCK), secretin gene expression and pancreatic secretion were examined in CCK-A-receptor-deficient (OLETF) rats. The rats were fed chow containing 0.1% trypsin inhibitors for 7 days. To examine pancreatic secretion, the rats were prepared with cannulae to drain the bile and pancreatic juice separately, a duodenal cannula and an external jugular vein cannula. The animals were maintained in Bollman cages and the experiments were conducted 4 days after surgery. The levels of CCK mRNA were significantly increased by each treatment. The levels of secretin mRNA were significantly increased by camostate and SBTI, but not by ONO-3403. Bicarbonate secretion was significantly increased in rats treated with camostate and ONO-3403, but not SBTI, while protein secretion was not affected by any treatment. These observations suggest that increased bicarbonate secretion produced by synthetic trypsin inhibitors in CCK-A-receptor-deficient rats may not be due to secretin but due to ONO-3403 in the circulation.
Collapse
Affiliation(s)
- T Kawanami
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Matsusue K, Takiguchi S, Takata Y, Funakoshi A, Miyasaka K, Kono A. Expression of cholecystokinin type A receptor gene correlates with DNA demethylation during postnatal development of rat pancreas. Biochem Biophys Res Commun 1999; 264:29-32. [PMID: 10527835 DOI: 10.1006/bbrc.1999.1459] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cholecystokinin stimulates pancreatic amylase secretion, gallbladder contraction, and pancreatic growth, etc. by binding with high affinity to a cholecystokinin type A receptor (CCKAR). To better understand the expression of CCKAR mRNA in terms of tissue specificity and postnatal development, we determined the methylation status of BssHII sites (5'-B sites) in the rat CCKAR gene promoter. The 5'-B sites in adult pancreas expressing CCKAR mRNA were much less extensively methylated than those in fetal pancreas not expressing the mRNA. In brain, liver, and kidney of adult rats not expressing CCKAR mRNA, the 5'-B sites were methylated. In pancreas, the demethylation level of the sites increased at 21 days after birth. Concomitant with the DNA demethylation level in the 5'-B sites, the mRNA level rose rapidly in 21 days. These results demonstrate that methylation and expression of the CCKAR gene reveal a good inverse correlation.
Collapse
Affiliation(s)
- K Matsusue
- Division of Chemotherapy, Division of Gastroenterology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1347, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Tateishi K, Misumi Y, Ikehara Y, Miyasaka K, Funakoshi A. Molecular cloning and expression of rat antisecretory factor and its intracellular localization. Biochem Cell Biol 1999; 77:223-8. [PMID: 10505793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
Antisecretory factor (AF) was identified as a pituitary protein that inhibits the intestinal fluid secretion induced by cholera toxin. One aim of this study was to elucidate whether AF is also synthesized in the intestine or if AF produced in the pituitary is transported to the intestinal tract for its function there. cDNA clones encoding a protein proposed to be AF were isolated from rat pituitary gland and intestinal mucosa cDNA libraries. The nucleotide sequences of clones isolated from the rat pituitary gland and intestinal mucosa were identical. The deduced amino acid sequence was highly homologous to the sequence for subunit 5a of the human 26S protease that exists abundantly in the cytosol and nucleus. The production of AF in the intestine was confirmed by Northern blot and immunoblot analyses. Immunocytochemical observations of cells transfected with the rat AF cDNA showed that the AF protein was localized in the cytoplasm. These findings suggest that the protein proposed to be AF may be a cytoplasmic protein, it exists in the intestine rather than being transported from the pituitary gland, and it may function in intestinal cells.
Collapse
Affiliation(s)
- K Tateishi
- Department of Biochemistry, Fukuoka University School of Medicine, Japan.
| | | | | | | | | |
Collapse
|
46
|
Miyasaka K, Suzuki S, Kanai S, Masuda M, Funakoshi A. Role of CCK-A receptor in the regulation of pancreatic bicarbonate secretion in conscious rats: a study in naturally occurring CCK-A receptor gene knockout rats. Pancreas 1999; 19:217-23. [PMID: 10505751 DOI: 10.1097/00006676-199910000-00001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
Whether cholecystokinin (CCK) has a direct action on duct cells and the role of CCK-A receptor in bicarbonate secretion were examined by comparing the results obtained from OLETF (CCK-A receptor-deficient rats) and control (LETO) rats. Rats were prepared with cannulae for draining bile and pancreatic juice separately, with two duodenal cannulae and an external jugular vein cannula. The experiments were conducted without anesthesia. The responses of bicarbonate secretion to intravenous infusion of CCK, acetyl-beta-methylcholine (Ach), and 2-deoxy-D-glucose (2DG), and to intraduodenal infusion of HCl and a liquid meal were examined. To examine the synergistic effect between CCK and secretin, the effect of CCK during a background secretin infusion was examined in LETO rats. CCK did not stimulate bicarbonate secretion in either strain, nor in LETO rats with secretin infusion. When gastric acid secretion was prevented by administration of omeprazole, Ach did not increase bicarbonate secretion, but 2DG did in both strains. Intraduodenal infusion of HCI and a liquid meal significantly increased bicarbonate secretion in both strains; however, the responses were much less in OLETF than LETO rats. In conclusion, intravenous injection of CCK did not stimulate bicarbonate secretion, and the lack of CCK-A receptor decreased bicarbonate secretion in response to luminal stimulants.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan.
| | | | | | | | | |
Collapse
|
47
|
Miyasaka K, Shinozaki H, Suzuki S, Sato Y, Kanai S, Masuda M, Jimi A, Nagata A, Matsui T, Noda T, Kono A, Funakoshi A. Disruption of cholecystokinin (CCK)-B receptor gene did not modify bile or pancreatic secretion or pancreatic growth: a study in CCK-B receptor gene knockout mice. Pancreas 1999; 19:114-8. [PMID: 10438156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
Pancreatic exocrine function and bile secretion were examined in cholecystokinin (CCK)-B receptor gene-targeted mice and compared among different genotypes [i.e., CCK-B receptor gene: (+/+), wild-type; (+/-), heterozygous; and (-/-), homozygous deficient]. The histology and protein concentrations in the pancreas also were examined. Amylase release from the dispersed acini was examined in vitro by using the various doses of CCK-8, carbachol, and secretin. In vivo, the bile and pancreatic juice were collected, and the concentrations of amylase and bile acid were measured in anesthetized mice. The responses to CCK (100 pmol/kg) or acetyl-beta-methylcholine (500 nmol/kg) were examined. In vitro studies showed that the maximal effective concentrations of CCK-8 (10(-l0) M), carbachol (10(-5) M), and secretin (5 x 10(-7) M) were comparable for all genotypes. Fluid, amylase, and bile acid outputs in vivo also were comparable for all genotypes. Pancreatic wet weight and protein concentrations were not significantly different, and no abnormal findings were observed on histologic examination in any genotype. These results indicated that the CCK-B receptor has no role in pancreatic growth, exocrine secretion, or bile secretion in adult mice.
Collapse
Affiliation(s)
- K Miyasaka
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Cholecystokinin (CCK) is one of the most abundant neurotransmitter peptides in the brain. As OLETF rats lack CCK-A receptor because of a genetic abnormality, we examined whether learning and memory were impaired in these animals using an elevated eight-arm radial maze. After the completion of a radial maze study, the animals were sacrificed for histological examination of the brain. In some animals, long-term potentiation (LTP) in the hippocampus was measured. In the radial maze, the level of activity (seconds/entry) and the time remaining in the arms were significantly longer in OLETF rats. The number of errors was also significantly higher, and that of the correct choices was significantly lower in OLETF rats compared to the controls (LETO rats). The LTP of the population spike was significantly lower in the OLETF than in the LETO rats. No histological abnormalities were observed. From these observations, we concluded that learning and memory functions were impaired in the OLETF rats.
Collapse
Affiliation(s)
- S Nomoto
- Department of Central Nervous System, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Japan
| | | | | | | | | |
Collapse
|
49
|
Shimazoe T, Maetani M, Nakamura S, Yamanouchi S, Watanabe S, Miyasaka K, Kono A, Funakoshi A. Lowered entrainment function in the suprachiasmatic nucleus of Otsuka Long Evans Tokushima Fatty (OLETF) rats. Jpn J Pharmacol 1999; 80:85-8. [PMID: 10446761 DOI: 10.1254/jjp.80.85] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The entrainment function in the suprachiasmatic nucleus (SCN) of young non-diabetic Otsuka Long Evans Tokushima Fatty (OLETF) rats was studied. OLETF rats significantly needed more days for re-entrainment to a new light-dark cycle than control Long Evans Tokushima Otsuka (LETO) rats. We also assessed Fos expression in the SCN induced by dim light exposure. The number of Fos-immunoreactive cells was significantly decreased in 5- to 13-week-old OLETF rats compared with LETO rats. Moreover, the effect of glutamate on neuronal activity in the SCN of OLETF rats were investigated. In young non-diabetic OLETF rats, the phase delay in the SCN neuronal firing rhythm induced by 1 microM glutamate was significantly less than that in LETO rats. These results suggested that the entrainment function is reduced in OLETF rats before the onset of diabetes.
Collapse
Affiliation(s)
- T Shimazoe
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Funakoshi A, Kono A, Miyasaka K. Lack of appropriate citation. J Gastroenterol 1999; 34:296-7. [PMID: 10213138 DOI: 10.1007/s005350050263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|